Si è verificato un errore durante il caricamento della pagina.
Il nostro team è stato avvisato ma contattaci tramite il Widget assistenza email se il problema persiste.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 4,5x - 5,0x | 4,7x |
| Selected Fwd EBIT Multiple | 4,5x - 4,9x | 4,7x |
| Fair Value | ₩8.914 - ₩9.538 | ₩9.226 |
| Upside | 38,0% - 47,6% | 42,8% |
| Benchmarks | Ticker | Full Ticker |
| Korean Drug Co., Ltd. | A014570 | KOSDAQ:A014570 |
| ChoA Pharmaceutical Co., LTD. | A034940 | KOSDAQ:A034940 |
| WooGene B&G Co., Ltd | A018620 | KOSDAQ:A018620 |
| GL Pharm Tech Corp. | A204840 | KOSDAQ:A204840 |
| Kyung Nam Pharm Co.,Ltd. | A053950 | KOSDAQ:A053950 |
| Sinil Pharmaceutical Co., Ltd. | A012790 | KOSDAQ:A012790 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| A014570 | A034940 | A018620 | A204840 | A053950 | A012790 | ||
| KOSDAQ:A014570 | KOSDAQ:A034940 | KOSDAQ:A018620 | KOSDAQ:A204840 | KOSDAQ:A053950 | KOSDAQ:A012790 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 3.7% | NM- | -34.7% | NM- | NM- | 10.1% | |
| 3Y CAGR | -28.6% | NM- | -3.4% | NM- | NM- | 24.0% | |
| Latest Twelve Months | -38.9% | -11.8% | -66.3% | 45.2% | 93.3% | 8.8% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 13.3% | -7.8% | 1.9% | -22.3% | -5.9% | 14.7% | |
| Prior Fiscal Year | 8.3% | -14.0% | 1.2% | -12.4% | -6.1% | 15.7% | |
| Latest Fiscal Year | 5.6% | -15.7% | 0.4% | -6.8% | -0.4% | 17.0% | |
| Latest Twelve Months | 5.6% | -15.7% | 0.4% | -6.8% | -0.4% | 17.0% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 0.46x | 0.74x | 1.29x | 4.24x | 0.34x | 0.44x | |
| EV / LTM EBITDA | 5.5x | -6.2x | 17.3x | -1914.1x | 9.2x | 1.9x | |
| EV / LTM EBIT | 8.2x | -4.7x | 298.6x | -62.4x | -84.9x | 2.6x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -84.9x | -4.7x | 298.6x | ||||
| Historical EV / LTM EBIT | 2.6x | 5.7x | 23.1x | ||||
| Selected EV / LTM EBIT | 4.5x | 4.7x | 5.0x | ||||
| (x) LTM EBIT | 15,222 | 15,222 | 15,222 | ||||
| (=) Implied Enterprise Value | 68,266 | 71,859 | 75,452 | ||||
| (-) Non-shareholder Claims * | 34,007 | 34,007 | 34,007 | ||||
| (=) Equity Value | 102,274 | 105,867 | 109,460 | ||||
| (/) Shares Outstanding | 11.4 | 11.4 | 11.4 | ||||
| Implied Value Range | 8,990.10 | 9,305.93 | 9,621.76 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 8,990.10 | 9,305.93 | 9,621.76 | 6,460.00 | |||
| Upside / (Downside) | 39.2% | 44.1% | 48.9% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A014570 | A034940 | A018620 | A204840 | A053950 | A012790 | |
| Enterprise Value | 33,400 | 46,476 | 71,870 | 110,360 | 20,617 | 39,483 | |
| (+) Cash & Short Term Investments | 19,000 | 5,447 | 20,778 | 4,258 | 50,814 | 33,713 | |
| (+) Investments & Other | 331 | 3,068 | 6,082 | 3,012 | 16,560 | 727 | |
| (-) Debt | (81) | (24,689) | (31,658) | (14,650) | (37,587) | (433) | |
| (-) Other Liabilities | 0 | 2,815 | (41,622) | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 52,650 | 33,117 | 25,450 | 102,979 | 50,405 | 73,491 | |
| (/) Shares Outstanding | 10.9 | 31.0 | 28.9 | 77.0 | 78.1 | 11.4 | |
| Implied Stock Price | 4,825.00 | 1,069.00 | 881.00 | 1,338.00 | 645.00 | 6,460.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 4,825.00 | 1,069.00 | 881.00 | 1,338.00 | 645.00 | 6,460.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |